Corporate VC Arm of Global Pharma Invests in Early-Stage Therapeutics and Digital Health Solutions of Strategic Fit

9 Aug

A corporate venture capital arm of a global pharmaceutical invests in early stage healthcare companies of strategic interest to the parent pharmaceutical (typically seed or series A). The firm has a global mandate and is currently seeking new equity investment opportunities.

As a strategic investor, the firm makes direct equity investments in innovative start-ups aligned with the pharmaceutical’s areas of strategic focus. Among these areas are rare diseases, vaccines, digital health solutions, etc. The firm seeks products that are in preclinical or early clinical development and that have proof-of-concept data.

The firm has a flexible funding structure and is able to lead and co-lead rounds as well as co-invest with top tier life science investors. The firm seeks to be a long-term investor with board responsibilities either as a full seat or as an observer.

In addition to equity financing, the firm provides strategic and technical input to portfolio companies through the established expertise of their teams. The success of the firm is driven by the ability to invest in areas where the fund can provide a unique voice and insight, active portfolio company engagement and the facilitation of future strategic collaborations with the parent pharmaceutical.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: